Cargando…

Real-World Use of Albutrepenonacog Alfa, A Recombinant Coagulation Factor IX Albumin Fusion Protein, for Personalized Prophylaxis in Japanese Individuals With Hemophilia B: A Case Series

Currently, the mainstay of disease management for hemophilia B, a hemorrhagic disease caused by a congenital deficiency or molecular abnormalities of blood coagulation factor IX (FIX), is prophylaxis using FIX concentrate. On-demand injections of FIX concentrate may also be required, even during pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nagao, Azusa, Bingo, Masato, Yamaguchi, Tomoko, Fukutake, Katsuyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2023
Materias:	Internal Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909124/ https://www.ncbi.nlm.nih.gov/pubmed/36779089 http://dx.doi.org/10.7759/cureus.33573

Ejemplares similares

Excellent hemostatic control during cardiac surgery in a patient with hemophilia B treated with albutrepenonacog alfa (rIX‐FP): A case report
por: López‐Jaime, Francisco José, et al.
Publicado: (2023)

Postmarketing safety and effectiveness of recombinant factor IX (nonacog alfa) in Japanese patients with haemophilia B
por: Fukutake, Katsuyuki, et al.
Publicado: (2019)

Genetic analysis of carrier status in female members of Japanese hemophilia families
por: Shinozawa, Keiko, et al.
Publicado: (2021)

Coagulation Factor IX for Hemophilia B Therapy 
por: Orlova, N. A., et al.
Publicado: (2012)

Long‐term safety and efficacy of rIX‐FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B
por: Mancuso, Maria Elisa, et al.
Publicado: (2020)

Damoctocog Alfa Pegol for Hemophilia A Prophylaxis: An Italian Multicenter Survey
por: Zanon, Ezio
Publicado: (2023)

Surgery and Prophylaxis with Susoctocog-Alfa in Acquired Hemophilia: Case Series and Literature Review
por: Sella, Carola, et al.
Publicado: (2023)

Real-World Experience of People with Hemophilia A Receiving Turoctocog Alfa Pegol (N8-GP): Results from a Patient Experience Survey
por: Eichler, Hermann, et al.
Publicado: (2023)

Preclinical evaluation of a next-generation, subcutaneously administered, coagulation factor IX variant, dalcinonacog alfa
por: Nichols, Timothy C., et al.
Publicado: (2020)

Effects of coagulation factor concentrate prophylaxis in moderate and severe hemophilia A patients at a single hemophilia center in Korea
por: Moon, Byung Suk, et al.
Publicado: (2013)

Deletion of Coagulation Factor IX Compromises Bone Mass and Strength: Murine Model of Hemophilia B (Christmas Disease)
por: Larson, Emily A., et al.
Publicado: (2021)

Moroctocog Alfa (AF-CC) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Patients with Hemophilia A in India
por: Choraria, Nirmalkumar, et al.
Publicado: (2022)

Fusion of engineered albumin with factor IX Padua extends half‐life and improves coagulant activity
por: Lombardi, Silvia, et al.
Publicado: (2021)

Extended half-life factor IX prophylaxis up to every 21 days in hemophilia B: a longitudinal analysis of the efficacy and safety in selected adult patients
por: Pabinger, Ingrid, et al.
Publicado: (2023)

Compensated pathogenic variants in coagulation factors VIII and IX present complex mapping between molecular impact and hemophilia severity
por: Marín, Òscar, et al.
Publicado: (2019)

Nonacog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Patients with Moderately Severe or Severe Hemophilia B in India
por: Choraria, Nirmalkumar, et al.
Publicado: (2022)

CRISPR/Cas9‐mediated somatic correction of a novel coagulator factor IX gene mutation ameliorates hemophilia in mouse
por: Guan, Yuting, et al.
Publicado: (2016)

Long-Acting Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Children: Results of a Phase 3 Trial
por: Kenet, Gili, et al.
Publicado: (2016)

Treatment of hemophilia B: focus on recombinant factor IX
por: Franchini, Massimo, et al.
Publicado: (2013)

The Clinical Genetics of Hemophilia B (Factor IX Deficiency)
por: Miller, Connie H
Publicado: (2021)

Identification of deep intronic individual variants in patients with hemophilia A by next‐generation sequencing of the whole factor VIII gene
por: Inaba, Hiroshi, et al.
Publicado: (2017)

Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study
por: Lentz, Steven R., et al.
Publicado: (2022)

Assessment of Relative Bioavailability of Moroctocog Alfa and Moroctocog Alfa (AF‐CC) in Subjects With Severe Hemophilia A
por: Korth‐Bradley, Joan, et al.
Publicado: (2018)

Profile of efraloctocog alfa and its potential in the treatment of hemophilia A
por: George, Lindsey A, et al.
Publicado: (2015)

The Effect of Fluctuating Temperature on the Stability of Turoctocog Alfa for Hemophilia A
por: Napolitano, Mariasanta, et al.
Publicado: (2019)

Optimization of prophylaxis for hemophilia A
por: Herbert, Robert D., et al.
Publicado: (2018)

GlycoPEGylated recombinant factor IX for hemophilia B in context
por: Santagostino, Elena, et al.
Publicado: (2018)

Performance of a recombinant fusion protein linking coagulation factor IX with recombinant albumin in one‐stage clotting assays
por: Horn, C., et al.
Publicado: (2018)

An Unusual Case of Bleeding: Acquired Hemophilia A
por: Jahangiri, Omeed S, et al.
Publicado: (2023)

Efficacy of Nuwiq(®) (Simoctocog Alfa) in Patients with Hemophilia A Who Changed and Adhered to a Pharmacokinetic-Guided Prophylaxis Regimen in the NuPreviq Study
por: Pasi, K John
Publicado: (2021)

Indirect Treatment Comparison of Damoctocog Alfa Pegol versus Turoctocog Alfa Pegol as Prophylactic Treatment in Patients with Hemophilia A
por: Vashi, Parth, et al.
Publicado: (2021)

Correction: Optimization of prophylaxis for hemophilia A
por: Herbert, Robert D., et al.
Publicado: (2018)

Half-life–extended recombinant coagulation factor IX–albumin fusion protein is recycled via the FcRn-mediated pathway
por: Chia, Jenny, et al.
Publicado: (2018)

Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa
por: Lissitchkov, Toshko, et al.
Publicado: (2023)

Changes in the coagulation parameters in dogs with protein-losing enteropathy between before and after treatment
por: NAGAHARA, Takuro, et al.
Publicado: (2021)

Long-term outcomes of prophylaxis with a recombinant factor VIII Fc or recombinant factor IX Fc in patients with hemophilia previously treated on demand
por: Álvarez-Román, María-Teresa, et al.
Publicado: (2023)

Recombinant factor IX Fc for major surgery in hemophilia B: factor IX plasma activity levels and effective hemostasis
por: Shapiro, Amy D., et al.
Publicado: (2023)

Turoctocog alfa: an evidence-based review of its potential in the treatment of hemophilia A
por: Takedani, Hideyuki, et al.
Publicado: (2015)

Efficacy, Safety, and Pharmacokinetics of Beroctocog Alfa in Patients Previously Treated for Hemophilia A
por: Hyun, Shin Young, et al.
Publicado: (2015)

Cross-reacting Material-positive Hemophilia A Diagnosed in a Patient with a Spontaneous Thigh Hemorrhage
por: Saito, Tatsuya, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_8kpll4q7ehao9iffg2qn6brbrl